APRIL 13, 2020
The China “Provisions for Drug Registration” have been issued and will be implemented on July 1, 2020. The new Provisions are the first revision in 13 years. Here we highlight and analyse changes from the previous version.
MARCH 4, 2020
Whether you are a B2B business (an ingredient manufacturer) or a B2C business (a branded finished product or a retailer), it’s never too late to look into immunity claims of your products/ingredients in China market.
NOVEMBER 11, 2018
Mr Glenn Cross talked about the present and the future of commercialising and exporting Australian life sciences. He also shared valuable lessons and tips based on his life-long experience in the sector.
OCTOBER 31, 2018
Approached by the State Government of Victoria, I had the pleasure to do medical interpreting for 24 Shanghai hospital presidents for their Melbourne visit. Read how I helped bridge communications.
SEPTEMBER 5, 2018
Chinese consumer health market is growing fast. Western health businesses can have a sweet spot in China. Check out this insight article!
MARCH 1, 2018
As another Australian Chinese healthcare commercialisation series, this time the Melbourne HealthCare Drinks event was held on Friday 23rd February, co-organised with ACASE.
JULY 5, 2017
China Food and Drug Administration (CFDA) was approved as a new regulatory member of the ICH. We analyse this milestone and its impact in this article.
MAY 18, 2017
The China regulator announced four new draft regulations on drugs and medical devices. What’s the impact on overseas companies? Find out in this article.
APRIL 25, 2017
The draft regulation was approved by CFDA on 20–Jun-2017 and published on 11-Oct-2017, under the title of No. 35 CFDA Degree. There are only minor revisions compared to the original statements.
APRIL 21, 2017
The China aged care sector: senile finance, supplies, services and real estate are all in infancy, with huge potential to grow. What are the aged care business opportunities in China for a Western business?